Boehringer et al. v. InvaGen
Oct 25, 2018OUTCOME: Judgment for Defendant InvaGen
Represented a generic in an ANDA litigation successfully invalidating asserted patents covering Tradjenta® (linagliptin) and Jentadueto® (linagliption and metformin).
Robert Stanley Silver's Legal Cases (4)
Philadelphia, PA
Intellectual property Lawyer at Philadelphia, PA
Practice Areas: Intellectual Property, Patent Infringement
Roxane Labs Inc. v. Invagen Inc.
May 25, 2017OUTCOME: $2 million fee award to client
Successfully represented a defendant generic company facing a demand of $100 million in damages by defeating a preliminary injunction, (affirmed on appeal). After a finding of non-infringement, upheld ... on appeal, he obtained a $2 million fee award against Roxane for an “exceptional” case regarding calcium acetate tablets (PhosLo® brand).
Genzyme v. Pentech Pharmaceuticals, Inc.
Jan 01, 2009OUTCOME: Case Dismissed
Represented a generic in ANDA litigation on Hectorol® invalidating 2 Orange Book listed patents, with the third patent being delisted as a result of suit.
Sanofi and BMS v. Apotex
Jan 19, 2007OUTCOME: Assisted Apotex in launching $1 billion at risk launch, most profitable in history
Generic ANDA applicant Apotex sued for patent infringement on generic version of the drug Plavix.
Ad
Transform legal challenges into solutions.
Connect now to review your situation.
